If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD. BridgeBio Pharma Inc. – BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
https://curelgmd2i.com/2026/04/26/bridgebio-submits-nda-to-fda-for-bbp-418/